VALANX Biotech
Latest round
- Seed
Last raised
- Jan 2020
Total raised
- $0.1M
Investors
- 2
About VALANX Biotech
Founded in 2017 in Austria, VALANX Biotech GmbH develops site-specific protein conjugation platforms.VALANX Biotech specializes in a novel site-specific protein conjugation platform that enables precise control over the conjugation site and the number of conjugations on proteins of interest. This technology is aimed at developing biologics, with potential applications in various therapeutic areas, including immunology and oncology. The company’s flagship product, GoldenSite™, facilitates the development of conjugates that enhance the efficacy and safety of therapeutic proteins. VALANX's client base includes pharmaceutical and biotechnology companies focused on innovative drug development, especially those interested in synthetic biology for precision medicine.VALANX Biotech generates revenue through partnerships and collaborations with pharmaceutical and biotech firms that utilize its protein conjugation technology for drug development. Transactions typically involve service agreements and licensing arrangements, where clients pay for access to the GoldenSite™ platform or contract VALANX for specific research and development services. The revenue structure includes fees associated with service contracts, which vary based on project scope and complexity. VALANX might also engage in milestone payments tied to the progress of specific projects and royalties from successful commercialization of products developed using its technology, focusing on delivering high-value scientific solutions to its clients. VALANX Biotech aims to carry out preclinical studies, finalize its antibody-drug candidate, and prepare for manufacturing. Plans include launching new product offerings to enhance therapeutic efficacy. The company is also targeting expansion into new markets across Europe and North America by 2022.
Who invested in VALANX Biotech
2 investors across 2 rounds
See all investors in VALANX Biotech
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about VALANX Biotech
Who invested in VALANX Biotech?
VALANX Biotech has 2 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has VALANX Biotech raised?
VALANX Biotech has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did VALANX Biotech last raise money?
VALANX Biotech's most recent round on record is a Seed, in Jan 2020.
What does VALANX Biotech do?
Founded in 2017 in Austria, VALANX Biotech GmbH develops site-specific protein conjugation platforms.
Where is VALANX Biotech headquartered?
VALANX Biotech is headquartered in Vienna, Austria.
Which VCs invest in companies like VALANX Biotech?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Balderton Capital back biotechnology companies at VALANX Biotech's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like VALANX Biotech? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.